Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression

Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: Old targets new hope

(2013) Pradip De et al.   CANCER TREATMENT REVIEWS

The Combined Deletion of S6K1 and Akt2 Deteriorates Glycemic Control in a High-Fat Diet

(2012) C. Treins et al.   MOLECULAR AND CELLULAR BIOLOGY

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

(2012) Dimitrios Anastasiou et al.   Nature Chemical Biology

PPARγ contributes to PKM2 and HK2 expression in fatty liver

(2012) Ganna Panasyuk et al.   Nature Communications

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

(2011) Andrew X. Zhu et al.   CANCER

S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy

(2011) Catherine Espeillac et al.   JOURNAL OF CLINICAL INVESTIGATION

The Critical Role of AKT2 in Hepatic Steatosis Induced by PTEN Loss

(2010) Lina He et al.   AMERICAN JOURNAL OF PATHOLOGY

Expansion of Hepatic Tumor Progenitor Cells in Pten-Null Mice Requires Liver Injury and Is Reversed by Loss of AKT2

(2010) Vivian A. Galicia et al.   GASTROENTEROLOGY

Identification of small molecule inhibitors of pyruvate kinase M2

(2009) Matthew G. Vander Heiden et al.   BIOCHEMICAL PHARMACOLOGY

Akt2 Is Required for Hepatic Lipid Accumulation in Models of Insulin Resistance

(2009) Karla F. Leavens et al.   Cell Metabolism

mTOR inhibitors for hepatocellular cancer: a forward-moving target

(2009) Gerhard Treiber   Expert Review of Anticancer Therapy

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

(2008) Magnus Rizell et al.   International Journal of Clinical Oncology

Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation

(2008) Samira Alliouachene et al.   JOURNAL OF CLINICAL INVESTIGATION

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA